nach oben

Erschienen in:

09.03.2020 | Original Article

A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome

verfasst von: Gustavo Luiz Behrens Pinto, Renata Casseb de Souza Carboni, Fernando Henrique Carlos de Souza, Samuel Katsuyuki Shinjo

Erschienen in: Clinical Rheumatology | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The pro-inflammatory interleukin (IL)-17A serum has been characterized in several systemic autoimmune diseases, but not in antisynthetase syndrome (ASS). Therefore, the present study aims firstly to assess the serum level of the IL-17A in patients with ASS, comparing with healthy individuals, and secondly to analyze prospectively this IL in patients with refractory ASS undergoing rituximab treatment.

Materials and methods

A cross-sectional, single-center study that included 64 patients with ASS who were age-, gender-, and ethnicity-matched to 64 healthy individuals. Disease status was measured by the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. Secondarily, the patients with refractory disease treated with rituximab were prospectively followed for 12 months. The IL-17A was assessed by the ELISA method.

Results

The mean age of the patients was 44.8 ± 11.8 years, with a predominance of female gender and Caucasian. The median serum IL-17A level was higher in ASS patients compared with healthy individuals: 9.7 (9.1–10.4) vs. 7.7 (5.7–9.0) pg/mL, respectively, and P < 0.001. However, the demographical, clinical, and laboratory data indicates that disease status did not correlate with serum levels of the IL-17A in ASS patients. Prospectively, 16 patients received rituximab, and there was a drop of IL-17A serum level over the first year of treatment in these patients: from 9.7 (9.1–10.6) to 9.0 (8.2–9.7) pg/mL (P = 0.01).

Conclusions

Our study demonstrated that patients with ASS have increased serum levels of the IL-17A compared with healthy controls. In addition, the patients with refractory ASS treated with rituximab showed a reduction of the serum levels of the IL-17A.

Key Points
• Patients with ASS have increased serum levels of the IL-17A.
• Patients with refractory ASS treated with rituximab showed a reduction of the serum levels of the IL-17A.

Gallay L, Gayed C, Hervier B (2018) Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol 30:664–673CrossRef

Araujo PAO, Silva MG, Borba EF, Shinjo SK (2018) High prevalence of metabolic syndrome in antisynthetase syndrome. Clin Exp Rheumatol 36:241–247PubMed

Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138:1464–1474CrossRef

Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, Cordier JF, Cottin V (2014) The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 13:883–891CrossRef

Roşu A, Mǎrgǎritescu C, Stepan A, Muşetescu A, Ene M (2012) IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients. Romanian J Morphol Embryol 53:73–80

Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34:149–162CrossRef

Monin L, Gaffen SL (2018) Interleukin 17 family cytokines: signaling and therapeutic implications. Cold Spring Harb Perspect Biol 10:A028522CrossRef

Mitsdoerffer M, Lee Y, Jäger A, Kim HJ, Korn T, Kolls JK et al (2010) Pro-inflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 107:14292–14297CrossRef

Reed AM, Crowson CS, Hein M, De Padilla CL, Olazagasti JM, Aggarwal R et al (2015) Biologic predictors of clinical improvement in rituximab-treated refractory myositis clinical rheumatology and osteoporosis. BMC Musculoskelet Disord 16:257CrossRef

10.

Van De Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, DI Padova F, Koenders MI et al (2011) The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 63:1507–1516CrossRef

11.

Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Di Benedetto P et al (2016) Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren’s syndrome: a pilot study. Clin Exp Immunol 184:284–292CrossRef

12.

Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp 63:435–449CrossRef

13.

Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, Wu YW et al (2010) Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol 30:221–225CrossRef

14.

Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H (2018) Expression of interleukin-17 in primary Sjögren’s syndrome and the correlation with disease severity: a systematic review and meta-analysis. Scand J Immunol 87:e12649CrossRef

15.

Silva MG, Oba-Shinjo SM, Marie SKN, Shinjo SK (2018) Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 37:656–662PubMed

16.

Notarnicola A, Lapadula G, Natuzzi D, Lundberg IE, Iannone F (2015) Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. Scand J Rheumatol 44:224–228CrossRef

17.

Tournadre A, Miossec P (2012) Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 14:252–256CrossRef

18.

Shen H, Xia L, Lu J, Xiao W (2011) Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 40:217–220CrossRef

19.

Moran EM, Mastaglia FL (2014) The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord 24:943–952CrossRef

20.

Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P (2003) Interleukin-17 increases the effects of IL-1 h on muscle cells : arguments for the role of T cells in the pathogenesis of myositis. J Neuro-Oncol 137:125–133

21.

Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N, International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation (2017) 2016 American College of Rheumatology/European League against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis. Ann Rheum Dis 76:782–791CrossRef

22.

Rider LLG, Koziol D, Giannini EEH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472CrossRef

23.

Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:1–6CrossRef

24.

Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1462–1473CrossRef

25.

Cruellas MG, Dos Santos VV, Levy-Neto M, Souza FHC, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68:909–914CrossRef

26.

Souza FHC, Araújo DB, Vilela VS, Bezerra MC, Simões RS, Bernardo WM et al (2019) Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol 59:6CrossRef

27.

Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ (2011) Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 41:674–679CrossRef

28.

Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44:1051–1057CrossRef

29.

Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C et al (2017) A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 56:999–1007CrossRef

30.

Souza FHC, Cruellas MGP, Levy-Neto M, Shinjo SK (2013) Síndrome antissintetase: Anti-PL-7, anti-PL-12 and anti-EJ. Rev Bras Reumatol 53:352–357CrossRef

31.

Hervier B, Benveniste O (2013) Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 15:349CrossRef

32.

Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367–371CrossRef

33.

Sem M, Molber Ø, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome - a retrospective case series. Rheumatology 48:968–971CrossRef

34.

Souza FHC, Miossi R, De Moraes JCB, Bonfá E, Shinjo SK (2018) Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol 58:31CrossRef

35.

Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83CrossRef

Titel: A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome
verfasst von: Gustavo Luiz Behrens Pinto
Renata Casseb de Souza Carboni
Fernando Henrique Carlos de Souza
Samuel Katsuyuki Shinjo
Publikationsdatum: 09.03.2020
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 9/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05013-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome

Abstract

Objectives

Materials and methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Abstract

Objectives

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2020

Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren’s syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis

Large vessel disease as a potentially treatable cause of devastating critical digital ischaemia in systemic sclerosis

Switching to teleconsultation for rheumatology in the wake of the COVID-19 pandemic: feasibility and patient response in India

Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis

A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab

The decreased expression of IKBKE in systemic lupus erythematosus

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin